A rising number of long-term survivors and potential long-term outcome related to the treatment isone of the most important issue due to the advances of management in cancer. The development ofsecondary malignancy has been reported in a number of cohorts. We present a case of breast cancerpatient developing acute myeloid leukemia (AML)- M5 within a relatively short interval of two and ahalf years from her primary treatment with adjuvant chemotherapy with 4 cycles of doxorubicin andcyclophosphamide, followed by 4 cycles of three weekly paclitaxel (AC-T) and radiotherapy. Whatcould be attributed to the occurrence of secondary leukemia in this patient will be discussed
Objective: To evaluate in a multicenter retrospective study, the clinical and laboratory characteris...
Introduction. Imatinib mesylate (IM) remains a treatment of choice for chronic myeloid leukemia (CML...
Acute Myelogenous Leukemia (AML) is an aggressive hematologic malignancy that cause by abnormal prol...
A rising number of long-term survivors and potential long-term outcome related to the treatment is o...
We report a case of cancer breast developing acute myeloid leukemia (AML) within a relatively short ...
We report a case of cancer breast developing acute myeloid leukemia (AML) within a relatively short ...
Abstract. Breast cancer is the most frequent cancer among women and the leading cause of death amon...
Breast cancer is the most frequent cancer among women and the leading cause of death among middle-ag...
The occurrence of myelodysplastic syndrome or acute myeloid leukemia has been reported after treatme...
Second malignancy is one of the late complications of long-term cancer survivors, treated with radia...
Hodgkin's Disease (HD) is a curable malignancy even in Nigeria, our limitations in health care deliv...
This study evaluates the risk of acute myeloid leukaemia (AML) in patients treated for breast cancer...
We report a patient with therapy-related acute promyelocytic leukemia (APL) that may have been cause...
Background and Objectives. The term secondary leukemia is usually employed to indicate both forms of...
Introduction: Within the framework of the GIMEMA Study Group, the characteristics of acute lymphoid ...
Objective: To evaluate in a multicenter retrospective study, the clinical and laboratory characteris...
Introduction. Imatinib mesylate (IM) remains a treatment of choice for chronic myeloid leukemia (CML...
Acute Myelogenous Leukemia (AML) is an aggressive hematologic malignancy that cause by abnormal prol...
A rising number of long-term survivors and potential long-term outcome related to the treatment is o...
We report a case of cancer breast developing acute myeloid leukemia (AML) within a relatively short ...
We report a case of cancer breast developing acute myeloid leukemia (AML) within a relatively short ...
Abstract. Breast cancer is the most frequent cancer among women and the leading cause of death amon...
Breast cancer is the most frequent cancer among women and the leading cause of death among middle-ag...
The occurrence of myelodysplastic syndrome or acute myeloid leukemia has been reported after treatme...
Second malignancy is one of the late complications of long-term cancer survivors, treated with radia...
Hodgkin's Disease (HD) is a curable malignancy even in Nigeria, our limitations in health care deliv...
This study evaluates the risk of acute myeloid leukaemia (AML) in patients treated for breast cancer...
We report a patient with therapy-related acute promyelocytic leukemia (APL) that may have been cause...
Background and Objectives. The term secondary leukemia is usually employed to indicate both forms of...
Introduction: Within the framework of the GIMEMA Study Group, the characteristics of acute lymphoid ...
Objective: To evaluate in a multicenter retrospective study, the clinical and laboratory characteris...
Introduction. Imatinib mesylate (IM) remains a treatment of choice for chronic myeloid leukemia (CML...
Acute Myelogenous Leukemia (AML) is an aggressive hematologic malignancy that cause by abnormal prol...